Panel Discussion: Balancing Potency, Specificity & Therapeutic Index to Ensure Safe RNAi Therapies

• Understanding the drivers of RNAi-related toxicity
• Optimizing delivery, chemistry & dosing to improve therapeutic index
• Building confidence in safety as RNAi expands beyond the liver

Speakers:

Nicole Lykens

Co Founder & Chief Technology Officer

Valaya Bio

Julia Alterman

Assistant Professor

UMass Chan Medical School

Jimmy Weterings

Vice President, Head Oligonucleotide Therapeutics

Bonito Biosciences

Swetha Rajasekaran

Senior Scientist

Alltrna